The US market may offer significant opportunity, but headline market size alone cannot support an entry decision. Product fit, application pathway, competition and execution capability must be assessed together.
1. Validate the opportunity at product level
Translate total market data into the patient, channel and customer segments the product can realistically reach. Official resources such as Drugs@FDA and the Orange Book provide a starting point for the approved-product and competitive landscape.
2. Choose the entry model
Direct operations, licensing, distribution and commercial-service partners create different trade-offs in control, investment, speed and risk. The decision should reflect long-term US objectives rather than cost alone.
- Define the capabilities that should remain internal.
- Document partner-selection criteria.
- Clarify decision rights and reporting responsibilities.
- Set measurable readiness criteria before launch.
3. Build one execution roadmap
Regulatory, supply, pricing, channel, sales and data plans cannot remain disconnected. Bring dependencies, decision owners and target dates into one commercial-readiness roadmap.
Kaynaklar / Sources
- FDA — How Drugs are Developed and Approved
- FDA — Abbreviated New Drug Application (ANDA)
- FDA — Orange Book
This article is for general information and is not legal, regulatory or medical advice. Confirm product-specific requirements with qualified specialists and the relevant authorities.
